Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist

Determinants of the short-term gastric damage caused by NSAIDs in man

BACKGROUND

The short-term gastric damage seen with non-steroidal anti-inflammatory drugs (NSAIDs) in man may involve inhibition of cyclooxygenase (COX-1) and COX-2 as well as the topical irritancy, which is dependant on the acidity (pKa) and/or lipophilicity (log P(7.4)).

AIM

To study the quantitative relationship between NSAID-induced short-term gastric damage, their physicochemical properties and contrasting roles of COX-1 and COX-2 inhibition.

METHODS

We identified studies that allowed a qualitative comparison of the gastric injury (Lanza scores) induced by NSAIDs with their pKa and log P(7.4). Damage was correlated with gastric COX inhibition and potency to inhibit COX-1 and 2 and their COX-2/COX-1 selectivity ratio.

RESULTS

The gastric damage correlates significantly with pKa (r = -0.69; P < 0.01), log P (r = -0.58, P < 0.05) and potency of the NSAIDs to inhibit COX-1 (r = -0.61, P < 0.02), but not with COX-2 inhibition or COX-2/COX-1 selectivity.

CONCLUSION

Against a background of COX-1 and COX-2 inhibition, the physicochemical properties of NSAID appear to play an important role in short-term gastric damage.

Endothelin-1-dependent up-regulation of leptin production in gastric mucosal injury by indomethacin

Leptin, a multifunctional hormone that regulates food intake and metabolic and endocrine responses, has emerged recently as an important modulatory factor in gastric mucosal resistance to injury. In this study, we applied the animal model of gastric mucosal injury caused by indomethacin to investigate the role of endothelin-1 (ET-1) in the mucosal leptin production. Using groups of rats subjected to intragastric administration of indomethacin (at 0-60 mg/kg), we show that gastric mucosal damage reached a maximum 4 h following the drug, and was accompanied by a marked elevation (up to 3.5-fold) in the mucosal leptin level, up to 4-fold enhancement in the expression of endothelin-converting enzyme-1 (ECE-1) activity and up to 4.5-fold increase in ET-1 generation. Pretreatment with phosphoramidon, an inhibitor of ECE-1 activity, not only led to a decline in ECE-1 and ET-1 generation, but also produced a dose-dependent reduction in the mucosal level of leptin and the extent of mucosal damage caused by indomethacin. This effect of phosphoramidon, however, was subject to suppression by the exogenous ET-1 administration. Moreover, a marked drop in the mucosal level of leptin and the reduction in the severity of mucosal damage was attained following pretreatment with ET(A) receptor antagonist BQ610, but not by ET(B) receptor antagonist BQ788. The results implicate ET-1 as a key factor in the regulation of leptin production associated with gastric mucosal response to injury, and show that the stimulatory effect of ET-1 on leptin production occurs via ET(A) receptor activation.

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

Bosentan, a dual endothelin receptor antagonist, is indicated for the treatment of patients with pulmonary arterial hypertension (PAH). Following oral administration, bosentan attains peak plasma concentrations after approximately 3 hours. The absolute bioavailability is about 50%. Food does not exert a clinically relevant effect on absorption at the recommended dose of 125 mg. Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h. The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state. Steady-state concentrations are achieved within 3-5 days after multiple-dose administration, when plasma concentrations are decreased by about 50% because of a 2-fold increase in clearance, probably due to induction of metabolising enzymes. Bosentan is mainly eliminated from the body by hepatic metabolism and subsequent biliary excretion of the metabolites. Three metabolites have been identified, formed by cytochrome P450 (CYP) 2C9 and 3A4. The metabolite Ro 48-5033 may contribute 20% to the total response following administration of bosentan. The pharmacokinetics of bosentan are dose-proportional up to 600 mg (single dose) and 500 mg/day (multiple doses). The pharmacokinetics of bosentan in paediatric PAH patients are comparable to those in healthy subjects, whereas adult PAH patients show a 2-fold increased exposure. Severe renal impairment (creatinine clearance 15-30 mL/min) and mild hepatic impairment (Child-Pugh class A) do not have a clinically relevant influence on the pharmacokinetics of bosentan. No dosage adjustment in adults is required based on sex, age, ethnic origin and bodyweight. Bosentan should generally be avoided in patients with moderate or severe hepatic impairment and/or elevated liver aminotransferases. Ketoconazole approximately doubles the exposure to bosentan because of inhibition of CYP3A4. Bosentan decreases exposure to ciclosporin, glibenclamide, simvastatin (and beta-hydroxyacid simvastatin) and (R)- and (S)-warfarin by up to 50% because of induction of CYP3A4 and/or CYP2C9. Coadministration of ciclosporin and bosentan markedly increases initial bosentan trough concentrations. Concomitant treatment with glibenclamide and bosentan leads to an increase in the incidence of aminotransferase elevations. Therefore, combined use with ciclosporin and glibenclamide is contraindicated and not recommended, respectively. The possibility of reduced efficacy of CYP2C9 and 3A4 substrates should be considered when coadministered with bosentan. No clinically relevant interaction was detected with the P-glycoprotein substrate digoxin. In healthy subjects, bosentan doses >300 mg increase plasma levels of endothelin-1. The drug moderately reduces blood pressure, and its main adverse effects are headache, flushing, increased liver aminotransferases, leg oedema and anaemia. In a pharmacokinetic-pharmacodynamic study in PAH patients, the haemodynamic effects lagged the plasma concentrations of bosentan.

Changes in endothelin-1 gene expression in the gastric mucosa of rats under cold-restraint-stress

OBJECTIVE

To investigate in rats the role of endothelin (ET)-1 gene expression in the development and progression of acute gastric mucosal lesions (AGML) induced by stress, and the effect of BQ-123 (a special ETA receptor antagonist) on the AGML.

METHODS

A rat model of gastric ulcer induced by cold-restraint-stress (CRS) was used. ET-1 concentrations in the plasma and gastric mucosa were determined by radioimmunoassay (RIA), gastric mucosa blood flow (GMBF) was measured with a laser Doppler flow meter, the ulcer index (UI) was used to estimate the degree of gastric mucosa damage and the expression levels of ET-1 mRNA in the gastric mucosa were measured using dot blot and reverse transcription polymerase chain reaction (RT-PCR). Different doses of BQ-123 were administered via the left femoral vein prior to the stress in order to observe the effects of BQ-123 on the ET-1 concentrations in the plasma and gastric mucosa, the GMBF and the UI.

RESULTS

Compared with the normal controls, the ET-1 concentrations in the plasma and gastric mucosa of the stressed rats were increased significantly (P < 0.05), the GMBF was decreased markedly (P < 0.01), and the UI increased dramatically (P < 0.01). There was a significant positive correlation between the gastric mucosal EF-1 concentration and the UI (r = 0.98, P < 0.01), and a significant negative correlation between the gastric mucosal ET-1 concentration and GMBF (r = -0.89, P < 0.01) and also between the UI and GMBF (r = -0.98, P < 0.01). The expression level of ET-1 mRNA in the gastric mucosa of the stressed rats increased significantly compared with that of the normal controls (P < 0.01), and there was a positive correlation between the expression of ET-1 mRNA and the ET-1 concentration in the gastric mucosa (r = 0.93, P < 0.01). Compared with the untreated animals, the GMBF was increased (P < 0.01) and the UI decreased significantly (P < 0.01) in the BQ-123-treated rats, and the dose of BQ-123 correlated with the degree of change in the GMBF and UI; however, the ET-1 concentrations of either the plasma or the gastric mucosa did not change markedly in the BQ-123-treated animals (P > 0.05).

CONCLUSION

The present study showed that the level of expression of ET-1 mRNA and the synthesis of ET-1 in the gastric mucosa both increased significantly, which suggests that the increased concentration of endogenous ET-1 may be involved in the development and progression of stress ulcer (acute gastric mucosa lesion). The mechanism of action may be associated with a reduction of GMBF induced by ETAR-mediated vasoconstriction. BQ-123 can dose-dependently attenuate significantly the degree of damage to the gastric mucosa induced by stress, and may have therapeutic benefits for stress ulcer.

Protective effects of endothelin-1 antibody on stress induced lesion of gastric mucosa in rats

AIM

To explore the protective effects of endothelin-1 antibody (ET-1Ab) on acute gastric mucosa lesions induced by stress in rats.

METHODS

Stress ulcer induced by cold-restraint-stress(CRS) was used as model in this study, different dose ET-1Ab were administered by left femoral vein prior to stress so as to observe the effects of the drug on ET-1 levels in plasma and gastric mucosa, gastric mucosa blood flow(GMBF)and ulcer index(UI) of CRS rats.

RESULTS

(1) Compared with the normal control group, ET-1 levels of plasma and gastric mucosa and UI were increased significantly in the stress groups (116.2±4.7 mv and 125.1±4.2 mv vs 49.1±9.7 mv, 113.8±9.3 mv and 122.9±19.6 mv vs 52.3±10.3 mv, 28.6±1.85 mv and 51.2±5.93 mv vs 0, P<0.01), while GMBF were decreased markedly in stress groups (227.8±13.5 mv and 150.8±11.5 mv vs 405.8±23.3 mv, P<0.01).There was significantly positive correlation between ET-1 and UI (r = 0.96, P<0.01), and significantly negative correlation between ET-1 and GMBF(r = -0.91, P<0.01). (2) However, compared with the single-stress groups, ET-1 levels of plasma and gastric mucosa and UI were decreased significantly in ET-1Ab-stress groups (69.2±7.3 mv vs 116.2±24.7 mv, 80.6±12.3 mv vs 125.1±24.2 mv, 58.5±6.3 mv vs 113.8±29.3 mv, 68.9±9.6 mvvs 122.9±19.6 mv, 13.2±2.05 mv vs 28.6±1.85 mv, 25.8±3.62 mv vs 51.2±5.93 mv, P<0.01), GMBF were increased dramatically (329.8±16.3 mv vs 227.8±13.5 mv, 251.9±11.3 mv vs 150.8±1.5 mv, P<0.01), ET-1Ab can dose-dependently reduce levels of the ET-1 and UI, and improve GMBF significantly in cold-restraint-stress.

CONCLUSION

In the course of CRS-induced ulcers, endogenous ET-1 levels of plasma and gastric mucosa were increased significantly, and there were close relationship between ET-1 levels and UI. The increased ET-1 may involve in the pathogenesis of CRS-induced ulcers in rats by its vasoconstriction and marked reduction of GMBF. ET-1Ab can dose-dependently attenuate the degree of gastric mucosa lesions induced by CRS significantly. So it may have therapeutic effect for SU.

Endothelin: what does the radiologist need to know?

Endothelin (ET) is a potent endogenous vasoconstrictor peptide. It has been implicated in various pathological states since its discovery in 1988. The cardiovascular system and the kidneys are important sites for the action of this peptide. Two types of ET receptor, ETA and ETB, govern the biological effects of ET. Drugs that can prevent the endogenous synthesis of ET or block its binding to receptors may offer important therapeutic impact to patients with congestive heart failure, pulmonary hypertension and acute renal failure. Areas of particular interest to the radiologist include the role of ET in mediating some of the side effects of contrast media, particularly contrast medium nephropathy, and the involvement of ET in the pathogenesis of restenosis following angioplasty. This review outlines the basic biology of this important mediator and its role in health and disease.

Gastroduodenal mucosal defense

The gastroduodenal mucosa is a model system of defense with several structural levels and biologic strategies that are closely interrelated with each other to cope with the harmful ingredients of ingested food and the potentially deleterious effects of gastric acid and pepsin. Experimental and clinical research carried out during the review period added to the understanding of each component of the multiple mechanisms of gastroduodenal mucosal protection. In the first place, mucosal integrity is defended by the mucus gel barrier, the epithelial cell barrier, and the immune barrier. The properties of these barriers are maintained by adequate regulation of mucus production, bicarbonate secretion, mucosal microcirculation, and motor activity. These regulatory systems are alarmed by nociceptive neurons and the mucosal immune system which includes chemokine-secreting epithelial cells. The ultimate defense system is rapid repair of the injured mucosa under the control of several growth factors. Progressing insight into the network of mucosal defense not only will improve existing therapies of inflammation and ulceration but also will provide new leads for the management of functional diseases in the gastroduodenal region.

Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen

BACKGROUND

As non-steroidal anti-inflammatory drugs (NSAIDs) become available for over-the-counter use, it is important to define doses that would not cause undue gastroduodenal damage during the short periods for which self-medication with NSAIDs is licensed.

AIM

To establish what dose of ketoprofen most closely resembles the maximum dose of ibuprofen (400 mg t.d.s.) licensed for self-medication.

METHODS

We studied healthy volunteers in a double-blind double-dummy randomized crossover study. Each subject took, over four separate 10-day dosing periods, ibuprofen 400 mg t.d.s., ketoprofen 12.5 mg t.d.s., ketoprofen 25 mg t.d.s. or ketoprofen 50 mg t.d.s. Mucosal injury was assessed by endoscopy at baseline and on the 3rd and 10th day of each dosing period. Ex vivo gastric mucosal prostaglandin (PG) E2 evoked by vortex mixing was measured by radioimmunoassay. Serum thromboxane was also measured by radioimmunoassay.

RESULTS

Ketoprofen 50 mg t.d.s. suppressed prostaglandin synthesis to a significantly greater extent than ibuprofen and caused significantly more gastroduodenal injury. The profile of prostaglandin synthesis and injury on ketoprofen 12.5 mg t.d.s. most closely resembled that of ibuprofen 400 mg t.d.s.

CONCLUSIONS

Ketoprofen 12.5 mg t.d.s. is an appropriate dose for self-medication, which is likely to be similar to ibuprofen 400 mg t. d.s. in its effects on the stomach and duodenum.